Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
24/04/2025 13:26
April 24 (Reuters) - Zyversa Therapeutics Inc ZVSA.O: ZYVERSA THERAPEUTICS CEO ISSUES SHAREHOLDER LETTER ANNOUNCING TRANSFORMATIVE RESEARCH AND DEVELOPMENT TRENDS FOR INFLAMMASOME INHIBITORS, AND PROVIDES UPDATE ON INFLAMMASOME ASC INHIBITOR IC 100’S DEVELOPMENT STATUS Source text: ID:nGNX163Pxd Further company coverage: ZVSA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing